Japanese flu drug 'clearly effective' in treating coronavirus, says China
Shares in Fujifilm Toyama Chemical, which developed favipiravir, surged after praise by Chinese official Wed 18 Mar 2020
A laboratory technician prepares Covid-19 patient samples for semi-automatic testing Patients given the medicine in Shenzhen turned negative in a median of four days
Medical authorities in China have said a drug used in Japan to treat new strains of influenza appeared to be effective in coronavirus patients, Japanese media said on Wednesday.
Zhang Xinmin, an official at China’s science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients.
“It has a high degree of safety and is clearly effective in treatment,” Zhang told reporters on Tuesday.
"
See also:
" Favipiravir, also known as T-705, Avigan, or favilavir is an antiviral drug being developed by Toyama Chemical of Japan with activity against many RNA viruses. In February 2020 Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 disease. [url=https://en.wikipedia.org/wiki/Favipiravir]Wikipedia[/url] "
14 mins ago - Fujifilm Toyama Chemical developed favipiravir, sold under the brand Avigan. “It has a high degree of safety and is clearly effective in treatment,”
Japanese flu drug 'clearly effective' in treating coronavirus, says China
Shares in Fujifilm Toyama Chemical, which developed favipiravir, surged after praise by Chinese official Wed 18 Mar 2020
A laboratory technician prepares Covid-19 patient samples for semi-automatic testing Patients given the medicine in Shenzhen turned negative in a median of four days
Medical authorities in China have said a drug used in Japan to treat new strains of influenza appeared to be effective in coronavirus patients, Japanese media said on Wednesday.
Zhang Xinmin, an official at China’s science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients.
“It has a high degree of safety and is clearly effective in treatment,” Zhang told reporters on Tuesday.
"
See also:
" Favipiravir, also known as T-705, Avigan, or favilavir is an antiviral drug being developed by Toyama Chemical of Japan with activity against many RNA viruses. In February 2020 Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 disease. [url=https://en.wikipedia.org/wiki/Favipiravir]Wikipedia[/url] "
14 mins ago - Fujifilm Toyama Chemical developed favipiravir, sold under the brand Avigan. “It has a high degree of safety and is clearly effective in treatment,”
"
EvenOdd 发表于 3/18/2020 7:00:38 AM [url=https://forums.huaren.us/showtopic.aspx?topicid=2519774&postid=83192857#83192857][img][/img][/url]
China's health leadership announced they have found the Japanese-developed anti-influenza drug Avigan to be effective in treating COVID-19 disease patients.
Zhang Xinmin, China’s director of the National Center for Biotechnology Development said Avigan (Favipiravir) was found to be effective in 2 clinical trials completed in Wuhan and Shenzhen and involved 240 patients and 80 patients respectively.
During a conference in Beijing on March 17, 2020, Zhang said the medicine worked for coronavirus-related symptoms including pneumonia and had no obvious side effects.
Zhang said those who were given Avigan reported positive results after 4 days of therapy. This contrasts with a median of 11 days for those without the medication.
Zhang said more than 80 [url=https://www.coronavirustoday.com/2019-nCoV]COVID-19[/url] patients have participated in the clinical trial in The Third People's Hospital of Shenzhen, including 35 patients taking Favipiravir and 45 patients on a control group.
One of these clinical trials also found that X-rays confirmed improvements in lung conditions in about 91 percent of the patients who were given the medicine.
The director said he formally recommended the use of this medicine as a way to treat the COVID-19 disease, which is caused by the [url=https://www.coronavirustoday.com/SARS-Cov-2]SARS-CoV-2[/url] virus.
According to Zhang, a Chinese pharmaceutical company has been approved by the National Medical Products Administration to mass-produce the medication and ensure a stable supply.
China's health leadership announced they have found the Japanese-developed anti-influenza drug Avigan to be effective in treating COVID-19 disease patients.
Zhang Xinmin, China’s director of the National Center for Biotechnology Development said Avigan (Favipiravir) was found to be effective in 2 clinical trials completed in Wuhan and Shenzhen and involved 240 patients and 80 patients respectively.
During a conference in Beijing on March 17, 2020, Zhang said the medicine worked for coronavirus-related symptoms including pneumonia and had no obvious side effects.
Zhang said those who were given Avigan reported positive results after 4 days of therapy. This contrasts with a median of 11 days for those without the medication.
Zhang said more than 80 [url=https://www.coronavirustoday.com/2019-nCoV]COVID-19[/url] patients have participated in the clinical trial in The Third People's Hospital of Shenzhen, including 35 patients taking Favipiravir and 45 patients on a control group.
One of these clinical trials also found that X-rays confirmed improvements in lung conditions in about 91 percent of the patients who were given the medicine.
The director said he formally recommended the use of this medicine as a way to treat the COVID-19 disease, which is caused by the [url=https://www.coronavirustoday.com/SARS-Cov-2]SARS-CoV-2[/url] virus.
According to Zhang, a Chinese pharmaceutical company has been approved by the National Medical Products Administration to mass-produce the medication and ensure a stable supply.
... ...
"
EvenOdd 发表于 3/18/2020 7:48:29 AM [url=https://forums.huaren.us/showtopic.aspx?topicid=2519774&postid=83192988#83192988][img][/img][/url]
Referring to below, why then this drug was approved at first, and has been used for sometime for other applications?
" S. Korea not to use Japan's Avigan as coronavirus drug 10:27 March 16, 2020
The Ministry of Food and Drug Safety said it has decided not to import Avigan after a team of infectious disease experts here ruled there is not enough clinical data to prove the drug's efficacy.
Avigan was approved as a backup drug for reemergent influenza in Japan in 2014. However, it has not been used to treat regular flu because several animal studies showed potential fetal damage.
"Avigan has not only not shown efficacy during test studies but also there is not data on clinical trials conducted on patients," said Oh Myoung-don, an infectious disease expert. "The drug has also shown serious side effects, such as fetal deaths in animal studies."
回复1楼Czboy 不是疫苗。The injections given will not contain coronavirus itself, and instead are filled with potential treatments to establish whether they could cause side-effects.
专家
这个问题自然是厉害国军方最快
同为志愿者点赞！
+1
Japanese flu drug 'clearly effective' in treating coronavirus, says China
Shares in Fujifilm Toyama Chemical, which developed favipiravir, surged after praise by Chinese official
Wed 18 Mar 2020
A laboratory technician prepares Covid-19 patient samples for semi-automatic testing
Patients given the medicine in Shenzhen turned negative in a median of four days
[url=https://www.theguardian.com/world/2020/mar/18/japanese-flu-drug-clearly-effective-in-treating-coronavirus-says-china]https://www.theguardian.com/world/2020/mar/18/japanese-flu-drug-clearly-effective-in-treating-coronavirus-says-china[/url]
Medical authorities in China have said a drug used in Japan to treat new strains of influenza appeared to be effective in coronavirus patients, Japanese media said on Wednesday.
Zhang Xinmin, an official at China’s science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients.
“It has a high degree of safety and is clearly effective in treatment,” Zhang told reporters on Tuesday.
"
See also:
"
Favipiravir, also known as T-705, Avigan, or favilavir is an antiviral drug being developed by Toyama Chemical of Japan with activity against many RNA viruses. In February 2020 Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 disease. [url=https://en.wikipedia.org/wiki/Favipiravir]Wikipedia[/url]
"
And:
"[url=https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=7&cad=rja&uact=8&ved=2ahUKEwihlbHH8KPoAhV2zzgGHcM3CG4QFjAGegQIAhAB&url=https%3A%2F%2Fwww.caixinglobal.com%2F2020-03-18%2Fchina-says-japan-developed-drug-avigan-works-against-coronavirus-101530182.html&usg=AOvVaw3wJyTuiuCh1N6yA9ctPBE3]www.caixinglobal.com › china-says-japan-developed-drug-avigan-work...
[/url]
14 mins ago - Fujifilm Toyama Chemical developed favipiravir, sold under the brand Avigan. “It has a high degree of safety and is clearly effective in treatment,”
"
" [url=https://flybird.store/health/?p=69]https://flybird.store/health/?p=69[/url]
公費流感抗病毒藥劑AVIGAN®(FAVIPIRAVIR) [url=https://flybird.store/health/?cat=12]抗病毒藥劑[/url]
[url=https://flybird.store/health/?p=69]2018-07-11[/url][url=https://flybird.store/health/?author=1]kavaskm[/url][url=https://flybird.store/health/?p=69#respond]Leave a Comment on 公費流感抗病毒藥劑AVIGAN®(FAVIPIRAVIR)[/url]
一、 前言
為因應新型A 型流感病患之防疫/治療需求，本署已依WHO 多元儲備流感抗病毒
藥劑建議，向日本富士膠片株式會社採購儲備流感抗病毒藥劑Avigan®，為利該藥劑
之管理及使用，爰規劃訂定本使用方案。
二、 使用對象
符合疾病管制署公布之新型A 型流感通報定義者，經使用克流感及瑞樂沙等流感
抗病毒藥劑治療無效，且經醫師評估及病患/家屬同意使用者。
...
...
"
这个长庚医院的啥部长，这是高级黑吗？
"
China Endorses Avigan / Favipiravir For COVID-19 Disease Treatment
Avigan Favipiravir (T-705) is a broad-spectrum inhibitor of viral RNA polymerase
[url=https://www.precisionvaccinations.com/avigan-favipiravir-t-705-broad-spectrum-inhibitor-viral-rna-polymerase]https://www.precisionvaccinations.com/avigan-favipiravir-t-705-broad-spectrum-inhibitor-viral-rna-polymerase[/url]
China's health leadership announced they have found the Japanese-developed anti-influenza drug Avigan to be effective in treating COVID-19 disease patients.
Zhang Xinmin, China’s director of the National Center for Biotechnology Development said Avigan (Favipiravir) was found to be effective in 2 clinical trials completed in Wuhan and Shenzhen and involved 240 patients and 80 patients respectively.
During a conference in Beijing on March 17, 2020, Zhang said the medicine worked for coronavirus-related symptoms including pneumonia and had no obvious side effects.
Zhang said those who were given Avigan reported positive results after 4 days of therapy. This contrasts with a median of 11 days for those without the medication.
Zhang said more than 80 [url=https://www.coronavirustoday.com/2019-nCoV]COVID-19[/url] patients have participated in the clinical trial in The Third People's Hospital of Shenzhen, including 35 patients taking Favipiravir and 45 patients on a control group.
One of these clinical trials also found that X-rays confirmed improvements in lung conditions in about 91 percent of the patients who were given the medicine.
The director said he formally recommended the use of this medicine as a way to treat the COVID-19 disease, which is caused by the [url=https://www.coronavirustoday.com/SARS-Cov-2]SARS-CoV-2[/url] virus.
According to Zhang, a Chinese pharmaceutical company has been approved by the National Medical Products Administration to mass-produce the medication and ensure a stable supply.
...
...
"
Referring to below, why then this drug was approved at first, and has been used for sometime for other applications?
"
S. Korea not to use Japan's Avigan as coronavirus drug 10:27 March 16, 2020
[url=https://en.yna.co.kr/view/AEN20200316002400320]https://en.yna.co.kr/view/AEN20200316002400320[/url]
...
The Ministry of Food and Drug Safety said it has decided not to import Avigan after a team of infectious disease experts here ruled there is not enough clinical data to prove the drug's efficacy.
Avigan was approved as a backup drug for reemergent influenza in Japan in 2014. However, it has not been used to treat regular flu because several animal studies showed potential fetal damage.
"Avigan has not only not shown efficacy during test studies but also there is not data on clinical trials conducted on patients," said Oh Myoung-don, an infectious disease expert. "The drug has also shown serious side effects, such as fetal deaths in animal studies."
...
"
你说这些川普都做了，你自己视而不见。你说那些障碍都是奥巴马留下的遗产。
天，中国做疫苗就是正常，美国做就是阴谋。脑子都坏掉了啊！
请问一般临床一期二期需要多久啊？疫苗需要三期吗？为啥需要这么久才能上市呢？我知道FDA在这个特殊时候，速度很快的，应该不是瓶颈。